OBJECTIVE: To determine whether matrix metalloproteinase (MMP) inhibitor can provide therapeutic effects for @entity95 @entity3236 in vivo and to observe the side effects of this drug on surrounding intraocular structures. METHODS: Experimental research. New Zealand white @entity95 were undertaken phacoemulsification operation. @entity718 at different concentrations (100, 200 and 500   mol/L) and @entity718 negative control liqueur were infused into the capsule bags of the @entity95 at the end of operation and two days after the operation. The incidence of @entity3236 was assessed and the histological sections of posterior capsules were observed under microscope 12 weeks after the surgery. The anterior chamber response was observed on day 2 post-operatively. The changes of intraocular pressure were measured by day 2 and day 7. Corneal endothelial cells were observed under scanning electron microscope and iris, ciliary body and retina were observed under microscope on day 7. RESULTS: @entity718 significantly prevented @entity3236 (P = 0.007). No @entity3236 occurred on the @entity95 posterior capsule in eyes with 200 and 500   mol/L @entity718 on week 12 post-operatively in vivo. No cells were found on posterior capsule in 500   mol/L group, whereas lens epithelial cells and fibroblasts were found in the controls under microscope. No difference of anterior chamber flare between the eyes with @entity718 at different concentrations and the control group (P = 0.380) by day 2 after the operation. The intraocular pressure in eyes with @entity718 was the same as that in the control 2-days (F = 0.642, P = 0.597) and 7-days (F = 0.179, P = 0.909) post-operation. The corneal endothelial cells in eyes with 500   mol/L @entity718 arranged regularly and did not show any difference from that in the control eyes under scanning electron microscope 7-day after the operation. The iris, ciliary body and retina in eyes with 500   mol/L @entity718 were normal in appearance 7-day after the operation. CONCLUSIONS: MMP inhibitor can prevent @entity3236 effectively in @entity95 in vivo and does not cause damage to surrounding intraocular structures, suggesting that MMP inhibitor may become a medication used for the prevention of lens @entity3236 .

[Experimental study on effects of matrix metalloproteinase inhibitor on @entity3236 in XXXX ].

@entity95 :: ('9986', 'Species') :: ['rabbits', 'rabbit'] @entity3236 :: ('MESH:D058442', 'Disease') :: ['posterior capsule opacification', 'opacification'] @entity718 :: ('MESH:C078131', 'Chemical') :: ['GM6001']
@entity95 :: (9986,Species) :: ['rabbits']
